tbuckley/cabot-search huggingface dataset:
Association of Constellations of Parental Risk With Children’s Subsequent Anxiety and Depression
Authors: Ingunn Olea Lund, Svetlana Skurtveit, Marte Handal, Anne Bukten, Fartein Ask Torvik, Eivind Ystrøm, Jasmina Burdzovic Andreas
Journal: JAMA Pediatrics (2019)

<h3>Importance</h3> The research focus on children of parents with alcohol use disorder has eclipsed the potentially wider-reaching detrimental effects of subclinical parental drinking, both alone and in combination with other parental risk factors. <h3>Objective</h3> To identify constellations of early parental risk characterized by variations in drinking, mental health, and education in both parents and examine their prospective associations with children’s contact with the health care system for anxiety and/or depression (ie, diagnoses or treatment). <h3>Design, Setting, and Participants</h3> This prospective study was based on linked survey and health registries data. The sample included 8773 children from 6696 two-parent families in Norway who participated in the Nord-Trøndelag Health Study (HUNT) survey in 1995 to 1997 or 2006 to 2008, when the children were aged 13 to 19 years. Data were analyzed from January to September 2018. <h3>Exposures</h3> Five constellations of early parental risks, characterized by variations in drinking frequencies and amounts, mental health, and education for both parents, as identified through latent profile analysis. <h3>Main Outcomes and Measures</h3> Children’s diagnoses or treatment of anxiety and/or depression from 2008 to 2016 were recorded in 3 health registries. The primary outcome was the total number of registries where participants presented (ranging from 0 to 3). <h3>Results</h3> Of the 8773 included children, 4404 (50.2%) were boys, and the mean (SD) age at the time of participation in the Nord-Trøndelag Health Study was 16.1 (1.8) years. Prevalence of anxiety and/or depression, as evidenced in at least 1 registry record, was 24.3% (2132 of 8773). Early parental risk profiles risks marked by (1) the lowest parental education (adjusted relative risk, 1.13; 95% CI, 1.01-1.25) and (2) elevated drinking in both parents and elevated mental health symptoms in fathers (adjusted relative risk, 1.52; 95% CI, 1.03-2.22) were associated with a significant increase in risk of anxiety and/or depression in children from those families compared with children from no-risk families. <h3>Conclusions and Relevance</h3> Studies seeking to understand prospective associations of parental drinking with children’s mental health need to consider additional risk factors in combination with one another as well as parental behaviors and characteristics below clinically defined levels. When accumulated at a family level, even seemingly innocuous characteristics contributed to meaningful increases in risk of anxiety and/or depression among children, potentially translating into poorer mental health outcomes for many young people.
Mantle cell lymphoma (MCL): A single-center experience from a tertiary care institute in south India.
Authors: Vishwanath Sathyanarayanan, K.C. Lakshmaiah, Kadabur Nagendrappa Lokesh, Clementina Rama Rao, Suresh TM, Kanaka Govind Babu, Premalata Chennagiri, Loknatha D, Linu Jacob Abraham, Suresh Babu
Journal: Journal of Clinical Oncology (2014)

e19547 Background: Mantle cell lymphoma (MCL), an aggressive B cell lymphoma accounts for 5-10% of Non- Hodgkin’s lymphoma. The incidence has increased and addition of rituximab to anthracycline based chemotherapy, bendamustine and allogenic stem cell transplantation are being used to improve survival but the prognosis remains poor. Methods: This retrospective study was conducted in Kidwai Memorial Institute of Oncology, Bangalore, India on diagnosed patients with Mantle cell lymphoma based on tissue biopsy, immunohistochemistry (characteristically cyclin D1) between January 2007 to December 2012. A total of 70 consecutive cases of Mantle cell lymphoma were included in the study. SPSS 15 software was used to tabulate the results. Results: The median age was 55 years (40- 72 years range); male and female ratio was 10:1. Eastern Co-operative Oncology Group ( ECOG) performance status of 0-2 in 88.5%.The presenting features were lymphadenopathy in 71.4%. B symptoms in 40%, gastrointestinal tract involvement in 17.1% and spenomegaly in 45.7%. The median Lactate dehydrogenase (LDH) was 229 U/L (range 169-1829 U/L). On Mantle cell lymphoma– International Prognostic Index (M-IPI), 44.2% were in low, 28.5% intermediate and 27.3% high risk. 52.87% had stage IV disease with bone marrow involved in 47.1 %. 9 out of 70 ( 12.85%) were having blastoid variant. 42 patients received treatment with COP or CHOP or R-CHOP regimens with overall response rate of 90%, 88% and 92% respectively. Kaplan Meier survival analysis was done. With a median follow up of 24 months, overall survival (OS) was 62%. Factors associated with short survival were poor ECOG performance status (PS), splenomegaly, B symptoms, high leukocyte count, high LDH, blastoid variant and high risk MIPI. Conclusions: MCL in our study presented mainly in > 50 years of age with advanced stage in > 50% of them and gastrointestinal tract was the most common extra nodal involvement. Blastoid variant and high risk MIPI were associated with poor overall survival. The overall response rate (ORR) with the current chemotherapeutic regimens is quite good. Newer chemotherapeutic regimens are required to improve the prognosis.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee
Authors: Aziz Nazha, Zhen-Huan Hu, Tao Wang, Betty K. Hamilton, Navneet S. Majhail, R. Coleman Lindsley, Ronald Sobecks, Uday Popat, Bart L Scott, Wael Saber
Journal: Blood (2018)
RPFNA cytologic atypia and short-term breast cancer risk in the prevention era.
Authors: Whitney L. Michaels, Carola Maria Zalles, Amy L Kreutzjans, Jennifer L Nydegger, Jessica A Box, Gwen M Hoefer, Bruce F. Kimler, Carol J. Fabian
Journal: Journal of Clinical Oncology (2014)

1521 Background: In 2000 we published our initial observation from a high risk cohort of 480 women that cytologic evidence of hyperplasia with atypia in tissue obtained by random periareolar fine needle aspiration (RPFNA) was associated with a 5 fold increased risk of developing DCIS or invasive breast cancer (IBC) at a median follow-up (FU) of 45 months (Fabian et al. JNCI 2000). Few women had any exposure to prevention agents as NSABP-P1 was not reported until 1998. We began a new high risk cohort in 2002 as our tissue processing methods changed to Thin Prep which provided better nuclear detail. Women in the 2ndcohort, in addition to counseling about standard prevention options, were given information about clinical trials and told that RPFNA atypia was a risk factor. The purpose of this initial analysis was to determine the predictive value of RPFNA atypia in the prevention era. Methods: A total 1,162 women, eligible on the basis of family history, prior LCIS or atypical hyperplasia and/or prior contralateral DCIS or IBC were enrolled in our 2nd cohort between 2002 and 2012. We used the same methods as with our earlier cohort where the first two aspiration results within 21 months were combined. The same cytopathologist (CZ) and same primary aspirator (CF) were utilized for both cohorts. Women were censored at the time of prophylactic mastectomy, development of other site cancer or death. 5 year Gail model risk, instead of 10 year Gail risk, was calculated for women 35 or older who did not have prior LCIS, DCIS or IBC. Kaplan-Meier hazard plots and Cox regression analysis were used for time to development of DCIS or IBC and effects of joint variables, respectively. Results: Median age at entry was 47 and 59% were premenopausal. 32% had cytologic evidence of atypia. At median FU of 55 months, neither 5 year Gail risk nor cytologic atypia was significantly predictive of subsequent development of breast cancer. However, 33% of women with atypia had taken a SERM or AI as part of a prevention trial and/or as standard of care and 12% of women <50 had a prophylactic oophorectomy. Conclusions: In a setting where many women with RPFNA atypia undergo a prevention intervention, cytologic atypia does not predict short term risk for breast cancer.
A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Sonia Christian, Pritesh Patel, Vaibhav Agrawal, Shawn Griffin, Kirk Cahill, Irum Khan, Karen Sweiss, Ardaman Shergill, Gregory Sampang Calip, Wendy Stock, Olatoyosi Odenike, Heiko Konig, John G. Quigley
Journal: Blood (2018)
Correlation of proteomics and first-line platinum-based chemotherapy in stage III/IV NSCLC in a large single-center cohort.
Authors: Thomas Christoph Gauler, Lydia Espenhain, Mathias Hoiczyk, Ivonne Nel, Annette Parr, Joanna Roder, Martin H. Schuler, Wilfried Ernst Erich Eberhardt, Heinrich Roder, Andreas Claudius Hoffmann
Journal: Journal of Clinical Oncology (2014)

e19104 Background: VeriStrat (VS), a protein test classifying serum samples as Good (VSG) or Poor (VSP) using mass spectral analysis, has been shown to be predictive of overall survival (OS) between treatment with EGFR-TKIs and single agent-chemotherapy in second-line NSCLC (Gregorc ASCO 2013). It has been shown (Vansteenkiste ESMO 2012) in the first-line with a gemcitabine-platinum regimen that VSG pts had better progression-free survival (PFS) and OS than VSP pts. It is of interest to investigate the potential utility of VS in other first-line NSCLC treatment regimens. Methods: In a retrospective cohort of patients (pts) with stage III/IV NSCLC, treated in first-line with platinum-based chemotherapy, we investigated the association of pre-treatment VS status with outcome. Pre-treatment VS classifications were generated blinded to clinical data. Pts were reevaluated every six to nine weeks regarding remission rate (RR )and PFS. The primary endpoint PFS. Results: Accrual was completed in Feb 2012. VS status and clinical data were available for seventy-five pts (60% male; 45% metastatic). Most of the patients received a platinum-taxane doublet (N=59); a smaller group (N=16) was treated with pemetrexed- or gemcitabine-based platinum regimens. Fifty-seven pts (76%) were classified as VSG and 18 (24%) as VSP. We observed in the VSG pts a RR of 38 % in contrast to 29 % in the VSP pts (p=0.57). Regarding PFS VSG pts had better outcomes than VSP pts overall, HR=0.54, p=0.042, with medians of 10 months (mos) and 6.5 months, respectively. HR between VS groups was numerically larger (HR=0.61) in the taxane-treated pts than in the small group of non-taxane-treated patients (HR = 0.38). Conclusions: VSP pts have poor outcomes when treated with platinum-doublets as first-line therapy for advanced NSCLC. It is of interest to investigate further whether this poorly-served population can achieve better outcomes on alternative therapies.
Colorectal cancer liver metastasis: Metastasectomy or intraoperative radiofrequency ablation?
Authors: Burcak Erkol, Gamze Kilicoglu, Metin Tilki, Mehmet Ali Uzun, Ali Surmelioglu, Basak Bala Oven, Ferhat Telli
Journal: Journal of Clinical Oncology (2014)

e14646 Background: Colorectal cancer is the fourth most frequently diagnosed cancer, and the second leading cause of cancer death in US. Most common localisation of metastasis are the lymph nodes and liver. With appropriate treatments, survival can be increased even if the patient in metastatic state. Individualised treatments can take a place in colorectal cancers as the other cancers. The aim of our study is to assess efficiency of liver metastasectomy and/or intraoperative radiofrequency ablation (RFA) in colorectal cancer liver metastasis. Methods: The file of 597 colorectal cancer patients, seen from 2007 to 2013, were reviewed for treatment modalities for their liver metastasis retrospectively. Results: Thirteen patients were female (30%) and 31 were male(70%). The median age was 60 years. There were 32 patients who undervent only metastasectomy, 12 metastasectomy and RFA, and three only RFA, in order of frequency. Tumor grade, T stage, and tumor localisation were found to be associated with disease-free survival (DFS) and overall survival (OS). When the subgroup analysis was performed in respectly presence of RFA there was no prognostic factor for survival. There was no DFS or OS difference between metastosectomy group, and metastasectomy RFA combined group. Median survival was 22, three months in RFA group, and 76 months in metastasectomy group (p: 0.38). Conclusions: Short median survival of RFA group can be due to advanced disease stage, and inoperability in the RFA group. RFA has the similar tolerable side effects, and can be use for the patients who can’t be operated completely.
Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial
Authors: Eva Hoster, Hanneke Kluin-Nelemans, Olivier Hermine, Jan Walewski, Marek Trneny, Christian H. Geisler, Stephan Stilgenbauer, Catherine Thieblemont, Ursula Vehling-Kaiser, Jeanette K. Doorduijn, Lionel Karlin, Roswitha Forstpointner, Herve Tilly, Michal Szymczyk, Vincent Ribrag, Marc Andre, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling
Journal: Blood (2017)
Investigations into the antiradition effects of BP-C2, a benzene-poly-carboxylic acid complex with molybdenum.
Authors: Stig Larsen, Fuad Fares, Steen Lindkaer Jensen
Journal: Journal of Clinical Oncology (2014)

11123 Background: BP-C2 is an innovative oral radio-protective drug based on a benzene-poly-carboxylic acid complex with molybdenum with important detoxifying properties and a new globular polydentant ligand BP-Cx-1 known for its detoxifying, free radical scavenging and anti-oxidant activity. We have previously demonstrated that administration of BP-C2 results in highly significant survival advantage in animals receiving either lethal or sub-lethal doses of gamma irradiation. LD50/30 6.56 GY. No adverse side effects using BP-C2 have been observed in vitro (LDH release) or in vivo. Methods: In the skin radiation injury prophylactic group, age matched white mice were treated with BP-C2 on the day of irradiation and hereafter treated three times a week for 5 weeks. In the post irradiation treatment group the animals were treated with BP-C2 three times per week for five weeks after the occurrence of skin injuries. The effects on skin injuries were investigated by H and E histopathology, cytokine and gene expression by immunohistochemistry. Animals were irradiated at 30 GY in the one hind leg. Results: All control mice developed severe skin injury in the leg. In contrast no skin injury was observed in mice treated prophylactically with BP-C2. In the treatment group with BP-C2 all mice were cured after five weeks of treatment. The expression of several oncogenes were decreased significantly whereas tumor suppressing genes where increased. BP-C2also stimulated the innate immune system.The effect is properly mediated via several cytokines (TNF-alpha, INF-gamma, GM-CSF, IL-1 beta, IL-6, Il-25) and apoptotic genes. Conclusions: BP-C2 has a potential for clinical use to protect patients from radiotherapy injuries of the skin prophylactically as well as post irradiation treatment.
Investigation of <i>mir-15a/mir-16-1 </i>expression levels in B-cell non-Hodgkin lymphomas.
Authors: Hulya Yazici, Seda Kilic, Mukaddes Avsar, Ozge Sukruoglu, Demet Akdeniz, Meltem Ekenel, Leyla Kilic, Adnan Aydiner, Bugra Tuncer
Journal: Journal of Clinical Oncology (2014)

e19533 Background: MicroRNAs (miRNA) are 21-23 nucleotide-long single-stranded RNA molecules that are not converted to proteins. Mature miRNA molecules show partial complementation to a part of one or more messenger RNAs (mRNAs) and regulate the expressions of binding genes. miRNAs can show tumor suppressor effect by inhibiting the expression of oncogenes and oncogenic effect by silencing tumor suppressor genes. Non-Hodgkin Lymphomas (NHLs) are strikingly heterogeneous in clinical course and in etiology because NHLs encompass a variety of histologically distinct forms. Non-Hodgkin Lymphoma occurence has risen steadily and dramatically in most parts of the world for several deacades. The interaction between miRNAs and cancer was reported in chronic lymphocytic leukemia (CLL) patients initially. In a majority of these patients the expression levels of miR-15-a and miR-16-1 were shown to be very low or none. In particular, B-cell lymphomas and chronic lymphocytic leukemias are derived from CD19+ and CD20+ B lymphocytes. There is no evidence of the expression levels of miR-15a and miR-16-1 genes in B cell lymphomas which come from the same cell lineage like CLL in literature. Methods: In this study, the expression levels of miR-15a and miR-16-1 genes in RNAs of peripheral lymphocytes for B-cell Non-Hodgkin Lymphoma patients and ethnicity, age and gender matched healthy controls were investigated using Real Time PCR. Results: In this study, the expression levels of miR-15a and miR-16-1 genes in RNAs of peripheral lymphocytes for B-cell Non-Hodgkin Lymphoma patients and ethnicity, age and gender matched healthy controls were investigated using Real Time PCR. The level of miR-16-1 gene expression was found 8,54-fold higher in the patient group compared with healthy controls (p<0.05) although the level of gene expression of miR-15a was not statistically different between patients and healthy controls (p>0.05). Conclusions: In our study, miR-16-1 gene was suppressed in patients with DLBCL, but not completely destroyed as shown in other studies. It also suggests that miR-16-1 is a tumor suppressor gene in DLBCL.
Retail Clinics Provide Important Antibiotic Stewardship
Authors: Marc-David Munk, Tobias Barker
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Comparison of Physiological Performance of Four Adaptive Servo Ventilation Devices in Patients with Complex Sleep Apnea
Authors: James Knitter, Omavi F. Bailey, Chithra Poongkunran, Aylene Flores Martinez, Linka Martinez, Ume Kobayashi, Daniel Combs, Richard Lane, Wojciech Zareba, Sairam Parthasarathy
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Adaptive servo ventilation (ASV) increased the risk for mortality in the SERVE-HF (Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure) trial, but the underlying mechanisms are unclear (1-3).Conceivably, device algorithms controlling respiratory rate and pressure support may have led to high _ VE that caused hypocapnia and consequent arrhythmias (2, 4, 5).Whether such findings are a result of a device algorithm-based effect ("device-effect") or apply to all servoalgorithm devices ("class-effect") is uncertain (2, 6).We compared the performance of various ASV devices on measures of respiration and electrocardiography.Some of the results of these studies have been previously reported in the form of an abstract (7).
Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial
Authors: Charlotte Pawlyn, Graham H Jackson, David Cairns, Alina Striha, Anna Hockaday, Gwen Jacques, John R Jones, Kevin Boyd, Bhuvan Kishore, Mamta Garg, Catherine Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew Jenner, Gordon Cook, Nigel H. Russell, Martin Kaiser, Mark T Drayson, Roger G. Owen, Walter M Gregory, Gareth Morgan, Faith E. Davies
Journal: Blood (2018)
A clinical study of pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity.
Authors: Zhang ming Jun
Journal: Journal of Clinical Oncology (2014)

e13514 Background: To evaluate the efficacy and safety of dexamethasone pretreatment regimen with different doses in the prevention of docetaxel-induced hypersensitivity reaction (HSR). Methods: One hundred and sixty-two patients were randomized into two groups. There were 90 patients in the study group and 72 patients in the control group. In the study group, patients received 4.5 mg of oral dexamethasone once a day. Patients in the control group received 8 mg of dexamethasone twice a day. All patients received dexamethasone for 3 days, from the day before docetaxel treatment to the day after docetaxel treatment. Results: In the study group, 10 patients had HSRs (11.1 %). While in the control group, 7 patients had HSRs (9.7 %). There was no statistically significant difference between these two groups (P =0.774). Conclusions: Since no significant difference in the HSR incidence between these two groups has been found, 4.5 mg of oral dexamethasone is as efficient and much safer compared to 8mg of oral dexamethasone.